ClinicalTrials.gg
RecruitingNCT07254572CASCADESUpdated Nov 28, 2025

Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

A Phase 4 interventional study of Semaglutide 14 MG [Rybelsus] and Dapagliflozin (Forxiga) in Coronary Artery Disease and PreDiabetes, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by National Institute of Cardiology, Warsaw, Poland · Phase 4, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · National Institute of Cardiology, Warsaw, Poland.

Planned enrollment
2nd of 12
300 · median 97
Started
2025
with 2 others
Phase 4
Only one
of the 18
Registered
17th of 18
by date

Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 4, and was the 17th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, or all of them as a file.
02

Study summary

The purpose of the study is to compare the anti-atherosclerotic efficacy of oral treatment with a GLP-1 analogue (semaglutide) or an SGLT-2 (so-called "flozin") inhibitor (dapagliflozin) versus routine treatment (metformin) in patients with pre-diabetes and diagnosed coronary artery disease at 24 months.

The diagnosis of coronary artery disease will be defined as the presence of coronary atherosclerosis confirmed by coronary artery computed tomography (coronary CT).

The study will evaluate the effect of treatment with flozin vs. semaglutide compared to treatment with metformin on the progression/regression of coronary atherosclerosis, change in plaque character, and control of cardiovascular risk factors.

03

Conditions studied

  • Coronary Artery Disease
  • PreDiabetes

Keywords

  • Coronary Artery Disease
  • Prediabetes
  • Coronary Plaque
  • Metformin
  • SGLT-2
  • GLP-1
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 - 80
  • Diagnosed coronary artery disease (coronary artery stenosis of at least 20% with a reference diameter of >2.5 mm or status after percutaneous coronary revascularization procedure found on coronary CT scan)
  • Coronary CT scan performed \<3 months after inclusion in the study, at least of good quality
  • Pre-diabetic status defined as fasting blood glucose 100-125 mg% or 5.70-6.49% (measurement documented at the screening/randomization appointment or within 30 days prior to the screening/randomization appointment) or documented, positive result of an oral glucose load test (fasting blood glucose 100-125 mg% and 140-199 mg% 2h after a 75 g oral glucose load) performed up to 30 days before the screening/randomization appointment
  • Stable treatment and control of cardiovascular risk factors, including dietary and lifestyle management for at least 4 weeks
  • Willing and able to give to participate in the study
  • Willing and able, according to the researcher, to comply with all the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • Severe valvular defect
  • Clinical condition requiring surgical treatment of coronary artery disease
  • Status after coronary artery bypass surgery
  • Diagnosed diabetes or >=6.5% at screening/randomization appointment
  • Other severe medical conditions requiring scheduled hospital treatment at the time of the study
  • Severe musculoskeletal conditions requiring specific rehabilitation recommendations
  • Diagnosed heart failure
  • Presence of an artificial valve, cardiac pacing system or other implantable device (such as a cardioverter defibrillator)
  • Severe arrhythmia/unexplained loss of consciousness
  • Other to physical activity
  • No consent to participate in the study
  • Use of glucose-lowering drugs other than metformin
  • Use of weight-loss drugs
  • Condition after bariatric surgery
  • Diagnosed liver disease or , AST above three times the at screening appointment
  • Uncompensated hyperthyroidism
  • Pancreatic cancer
  • Medullary thyroid cancer
  • History of anaphylactic shock after iodine contrast administration
  • Chronic kidney disease ( \<45 ml/min/1.73 m2)
  • History of pancreatitis or active pancreatitis
  • (BMI) >40 kg/m2
  • Pregnancy/lactation
  • Participation in another clinical trial
  • Other known contraindications to treatment with metformin, dapagliflozin or semaglutide
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    DAPAGLIFLOZIN

    Dapagliflozin + OMT \& Lifestyle Intervention

    Drug: Dapagliflozin (Forxiga) · Behavioral: Optimal Medical Therapy (OMT) And Lifestyle Intervention

  • Experimental
    SEMAGLUTIDE

    Semaglutide + OMT \& Lifestyle Intervention

    Drug: Semaglutide 14 MG [Rybelsus] · Behavioral: Optimal Medical Therapy (OMT) And Lifestyle Intervention

  • Active comparator
    METFORMIN

    Metformin + OMT \& Lifestyle Intervention

    Drug: Metformin · Behavioral: Optimal Medical Therapy (OMT) And Lifestyle Intervention

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Semaglutide 3 mg daily - up-titrated to 7 mg daily if well tolerated - up-titrated to 14 mg daily if well tolerated

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dapagliflozin 10 mg daily

  • Metformin 500 mg daily (up-titrated to 1000 mg daily if indicated)

  • BehavioralOptimal Medical Therapy (OMT) And Lifestyle Intervention

    * cardiological counselling aiming to reduce risk factors of atherosclerosis progression (LDL target, optimal medical therapy, comorbidities management, electrocardiogram) in accordance with current European Society of Cardiology guidelines * dietary counselling * body weight management * advice on optimizing physical activity levels * advice on how to quit smoking if applicable * psychological counselling

06

What researchers measure

Primary outcomes

  1. Evaluation of the effect of GLP-1 analogue treatment on coronary artery disease progression AND Evaluation of the effect of flozin treatment on the progression of coronary artery disease (CO-PRIMARY ENDPOINTS)

    Change in % volume of noncalcified atherosclerotic plaque in the coronary arteries assessed by coronary CT versus routine management (intention-to-treat) AND Change in % volume of noncalcified atherosclerotic plaque in the coronary arteries assessed by coronary CT versus routine management (intention-to-treat)

    Time frame: 24 months

Secondary outcomes

  1. Evaluation of the effect of each of the tested drugs vs. control group on progression of coronary artery disease

    % change in volume of noncalcified atherosclerotic plaque assessed by coronary CT (as treated) between baseline and end of study

    Time frame: 24 months

  2. Comparison of the effect of semaglutide vs. flozin on coronary artery disease progression

    % change in volume of noncalcified atherosclerotic plaque assessed by coronary CT (intention to treat/as treated) between baseline and end of study

    Time frame: 24 months

  3. Evaluation of the effect of each study drug vs. control group/comparison of the effect of semaglutide vs. flozin on progression of coronary artery disease

    % change in volume of the entire atherosclerotic plaque assessed by coronary CT) (intention to treat/as treated) between baseline and end of study

    Time frame: 24 months

  4. Evaluation of the effect of each of the tested drugs vs. control group/comparison of the effect of semaglutide vs. flozin on progression of coronary artery disease

    % change in volume of individual components of atherosclerotic plaque assessed by coronary CT (intention to treat/as treated) between baseline and end of study

    Time frame: 24 months

  5. Evaluation of the effect of each of the tested drugs vs. control group/comparison of the effect of semaglutide vs. flozin on progression of coronary artery disease (plaque conversion)

    Conversion of non-calcified plaque to calcified plaque assessed by coronary CT (intention to treat/as treated) between baseline and end of study

    Time frame: 24 months

  6. Evaluation of the effect of each of the tested drugs vs. control group/comparison of the effect of semaglutide vs. flozin on CV risk expressed as the dynamics of high-risk features

    Change in the number of high-risk atherosclerotic lesions defined as the presence of at least 2 high risk features among: * Spotty calcifications * Low attenuation plaques (low attenuation plaque, i.e. plaque density \<30 HU) * positive remodeling * napkin ring sign assessed by coronary TK (intention-to-treat/as treated) between baseline and end of study

    Time frame: 24 months

  7. Evaluation of the effect of each of the tested drugs vs. control group/comparison of the effect of semaglutide vs. flozin on CV risk on pericoronary fat attenuation index

    Change in the Pericoronary Fat Attenuation Index assessed by coronary TK (intention-to-treat/as treated) between baseline and end of study

    Time frame: 24 months

  8. Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - body weight

    Change in total body mass (expressed in kilograms) (intention-to-treat/as treated) between baseline and end of study

    Time frame: 24 months

  9. Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - body mass index

    Change in body mass index (BMI), calculated as following body mass index (BMI) = total body mass / (height)\^2 and expressed in kg/m2 (intention-to-treat/as treated) between baseline and end of study

    Time frame: 24 months

  10. Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - total body fat

    Change in totabl body fat mass (expressed in kilograms) measured by bioimpedance analysis (intention-to-treat/as treated) between baseline and end of study

    Time frame: 24 months

  11. Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - body cell mass

    Change in Body Cell Mass (BCM) (expressed in kilograms) measured by bioimpedance analysis (intention-to-treat/as treated) between baseline and end of study

    Time frame: 24 months

  12. Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - fat to mass ratio

    Change in fat to mass ratio (FMR), calculated as following fat to mass ratoi (FMR) = total body fat (TBF) / skeletal muscle mass measured by bioimpedance analysis (intention-to-treat/as treated) between baseline and end of study

    Time frame: 24 months

  13. Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - visceral fat area

    Change in visceral fat area (expressed in cm2) measured by bioimpedance analysis (intention-to-treat/as treated) between baseline and end of study

    Time frame: 24 months

  14. Evaluation of changes in anthropometric measurements in patients treated with semaglutide vs. patients treated with flozin - waist-to-hip index

    Change in waist-to-hip index (WHI) measured by bioimpedance analysis between baseline and end of study

    Time frame: 24 months

  15. Evaluation of change in inflammatory parameters in patients treated with semaglutide vs. patients treated with flozin

    Change in concentration of high-sensitivity C-reactive protein between baseline and end of the study

    Time frame: 24 months

  16. Evaluation of change in lipid levels in patients treated with semaglutide vs. patients treated with flozin

    Change in * total cholesterol * low-density lipoproteins (LDL) * high-density lipoproteins (HDL) * non-HDL cholesterol * triglycerides * lipoprotein A concentrations between baseline and end of the study

    Time frame: 24 months

  17. Evaluation of change in the percentage of glycated hemoglobin (HbA1c) in patients treated with semaglutide vs. patients treated with flozin

    Change in the percentage of glycated hemoglobin (HbA1c) between baseline and end of study

    Time frame: 24 months

  18. Evaluation of change in the percentage of patients with normal blood pressure in patients treated with semaglutide vs. patients treated with flozin

    Change in percentage of patients with normal blood pressure defined as systolic pressure \<140 mmHg and diastolic pressure \<90 mmHg between baseline and end of study

    Time frame: 24 months

  19. Evaluation of change in the percentage of patients smoking tobacco or electronic cigarettes in patients treated with semaglutide vs. patients treated with flozin

    Change in the percentage of patients smoking tobacco (cigarettes, pipe, cigar, tobacco heating products) or electronic cigarettes as defined by the study protocol between baseline and end of study

    Time frame: 24 months

  20. Evaluation of compliance with physical activity recommendations in patients treated with semaglutide vs. patients treated with flozin

    Change in * Percentage of patients classified in the "high" physical activity category; * Percentage of patients classified in the "sufficient" physical activity category; * Percentage of patients classified in the "insufficient" physical activity category between baseline and end of study

    Time frame: 24 months

  21. Evaluation of dietary compliance in patients treated with semaglutide vs. patients treated with flozin

    Change in the Dietary Approaches to Stop Hypertension (DASH) Index between baseline and end of study. For each of the 8 DASH food groups, a score of 10 is assigned when the DASH recommendation is met, lower intakes are scored proportionately, and the 8 individual scores are summed to create the overall DASH adherence score, which could range from 0 to 80. The higher the score, the better the adherence. Reference Günther AL, Liese AD, Bell RA, et al. Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus. Hypertension. 2009 Jan;53(1):6-12

    Time frame: 24 months

  22. Type 2 diabetes diagnosis

    Number of patients diagnosed with of diabetes based on the criteria of the Polish Diabetes Association during the study

    Time frame: 24 months

  23. Evaluation of the onset of heart failure requiring hospitalization

    Number of patients hospitalized for heart failure during the study

    Time frame: 24 months

  24. Number of unscheduled hospitalizations

    Number of unscheduled hospitalizations during the study

    Time frame: 24 months

  25. Number of major cardiovascular events and strokes (MACCE: death/myocardial infarction/revascularization/stroke) separately and combined

    Number of cardiovascular events and strokes (MACCE: death/myocardial infarction/revascularization/stroke) during the study

    Time frame: 24 months

  26. Homeostatic Model Change Assessment - Insulin Resistance (HOMA-IR)

    Change in Homeostatic Model Assessment - Insulin Resistance (HOMA-IR) between baseline and of study

    Time frame: 12 and 24 months

  27. Evaluation of change in the concentration of selected oxidative stress markers - catalase

    Change in plasma concentration of catalase between baseline and end of study

    Time frame: 12 months and 24 months

  28. Evaluation of change in the concentration of selected oxidative stress markers - superoxide dismutase (SOD)

    Change in plasma concentration of superoxide dismutase (SOD) between baseline and end of study

    Time frame: 12 months and 24 months

  29. Evaluation of change in the concentration of selected oxidative stress markers - Oxygen Radical Absorbance Capacity (ORAC)

    Change in concentration of Oxygen Radical Absorbance Capacity (ORAC) between baseline and end of study

    Time frame: 12 months and 24 months

  30. Evaluation of change in the concentration of selected oxidative stress markers - total antioxidant capacity (TAC)

    Change in concentration of total antioxidant capacity (TAC) between baseline and end of study

    Time frame: 12 months and 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-22/diabetes-total-risk-benefit-of-sglt2-inhibitors-and-glp1-agonists#.ZC8_KhOdj2E.link

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2029, 48 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 48 months is above that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Nov 28, 2025
StartActual
Jul 10, 2025
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07254572
Lead sponsor
National Institute of Cardiology, Warsaw, Poland
Collaborators
Medical Research Agency, Poland
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Jul 10, 2025
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Nov 28, 2025

Study contacts

Jan Henzel, MD, PhD
Contact
jhenzel@ikard.pl
+48 22 343 43 42
Kinga Kotlinska
Contact
kkotlinska@ikard.pl
+48 22 343 40 88
Jan Henzel, MD, PhD
principal investigator · National Institute of Cardiology
Mariusz Kruk, MD, PhD
study chair · National Institute of Cardiology
Cezary Kępka, MD, PhD
study chair · National Institute of Cardiology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Semaglutide · Dapagliflozin

Start the discussion